Financial Performance - The company's revenue for Q3 2023 was ¥212,469,441.09, a decrease of 2.75% compared to the same period last year[4] - Net profit attributable to shareholders was ¥19,075,141.71, down 62.74% year-on-year[4] - The basic earnings per share (EPS) was ¥0.0379, reflecting a decline of 62.73% compared to the previous year[4] - Total operating revenue for the period reached CNY 684,141,818.56, a slight increase from CNY 681,150,652.08 in the previous period, representing a growth of approximately 0.29%[19] - Net profit for the period was CNY 109,742,317.45, down from CNY 130,074,008.87, reflecting a decline of approximately 15.6%[21] - Earnings per share (EPS) decreased to CNY 0.2181 from CNY 0.2585, indicating a decline of about 15.6%[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,269,739,691.90, a decrease of 0.93% from the end of the previous year[4] - Total assets amounted to CNY 2,269,739,691.90, slightly down from CNY 2,290,944,050.05[18] - Total liabilities increased to CNY 405,548,766.63 from CNY 396,812,347.13, showing an increase of approximately 2%[18] - Total current assets as of September 30, 2023, amount to CNY 830,305,842.99, a decrease from CNY 865,402,215.15 at the beginning of the year[16] Cash Flow - Cash flow from operating activities for the year-to-date was ¥109,378,757.22, an increase of 9.74%[4] - The cash inflow from operating activities for the current period was CNY 784,850,845.91, an increase of 7.8% compared to CNY 727,909,881.30 in the previous period[22] - The net cash flow from operating activities was CNY 109,378,757.22, up from CNY 99,673,861.60, reflecting a growth of 7.1%[22] - Cash inflow from investment activities totaled CNY 795,118,314.05, significantly higher than CNY 105,725,650.98 in the previous period[22] - The net cash flow from investment activities was CNY 1,738,334.14, a recovery from a negative CNY 60,548,911.08 in the previous period[22] - Cash inflow from financing activities was CNY 103,094,444.48, down from CNY 151,504,745.40 in the previous period[23] - The net cash flow from financing activities was negative CNY 180,922,056.58, compared to a positive CNY 18,628,464.93 in the previous period[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 28,336[13] - Hainan Hansen Holdings holds 42.13% of the shares, making it the controlling shareholder[13] - The company has a total of 10 major shareholders, with the top 10 holding significant stakes[13] - The company does not have any preferred shareholders as per the report[14] Investment and Income - Investment income decreased by ¥26,522,813.57, a decline of 37.55% year-on-year, primarily due to reduced earnings from an associated company[8] - Other comprehensive income increased by 689.61% year-on-year, mainly due to improved earnings from an associated bank[9] - Other comprehensive income after tax was CNY 11,276,904.90, compared to a loss of CNY 1,912,591.42 in the previous period[21] Expenses - Total operating costs decreased to CNY 615,700,129.45 from CNY 622,255,079.62, marking a reduction of about 1.8%[19] - Research and development expenses were CNY 30,122,367.24, down from CNY 33,008,550.96, representing a decrease of approximately 8.6%[19] Cash and Equivalents - The company paid cash dividends of ¥150,960,000.00 during the reporting period, contributing to a 54.88% decrease in cash and cash equivalents[7] - Cash and cash equivalents decreased to CNY 65,600,648.70 from CNY 145,405,613.92[16] - The ending balance of cash and cash equivalents was CNY 65,600,648.70, a decrease from CNY 148,064,861.15 in the previous period[23]

湖南汉森制药股份有限公司 第六届监事会第三次会议决议的公告 证券代码：002412 证券简称：汉森制药 公告编号：2023-028 本公司及全体监事保证公告内容真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 - 1 - 监事会认为，公司会计政策变更是基于财政部下发的有关规定进行的，变更 后的会计政策能够客观、公允地反映公司的财务状况和经营成果，相关变更的决 策程序、信息披露等符合国家相关法律、法规、规章和规范性文件等规定，没有 损害公司及全体股东，特别是中小股东的利益。同意本次会计政策变更。 表决结果：3 票同意；0 票弃权；0 票反对。 一、监事会会议召开情况 湖南汉森制药股份有限公司（以下简称"公司"）第六届监事会第三次会议 于 2023 年 10 月 26 日在公司一楼会议室召开，本次会议由公司监事会主席刘赛 程女士召集主持，会议通知于 2023 年 10 月 17 日以专人递送、传真及电子邮件 等方式送达给全体监事。应参加会议监事 3 人，实际参加会议监事 3 人。本次 会议采取通讯会议的方式召开。本次会议的召集、召开符合《中华人民共和国公 司法》及《公司章程》的规定。 二、监事会会议审 ...

特别提示： 本次会计政策变更是依据中华人民共和国财政部（以下简称"财政部"）发 布的相关企业会计准则解释而进行的相应变更，无需提交公司股东大会审议，不 会对公司财务状况、经营成果和现金流量产生重大影响。 一、本次会计政策变更的概述 （一）变更的原因及变更日期 2022 年 11 月 30 日，财政部发布了《关于印发<企业会计准则解释第 16 号> 的通知》（财会〔2022〕31 号）（以下简称"准则解释第 16 号"），规定了 "关 于单项交易产生的资产和负债相关的递延所得税不适用初始确认豁免的会计处 理"的内容自 2023 年 1 月 1 日起施行；"关于发行方分类为权益工具的金融工 具相关股利的所得税影响的会计处理"及"关于企业将以现金结算的股份支付修 改为以权益结算的股份支付的会计处理"的内容，自公布之日起执行。 （二）变更前公司采用的会计政策 证券代码：002412 证券简称：汉森制药 公告编号：2023-030 湖南汉森制药股份有限公司 关于会计政策变更的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 三、董事会意见 本次会计政策变更经公司审计委员会审 ...

相关事项的独立意见 根据《上市公司独立董事规则》《深圳证券交易所股票上市规则》《公司章程》 等有关规定，我们作为湖南汉森制药股份有限公司（以下简称"公司"）独立董事， 现就公司第六届董事会第三次会议审议的议案，发表独立意见如下： 湖南汉森制药股份有限公司 独立董事关于公司第六届董事会第三次会议 经审核，我们认为：公司根据财政部颁布的《关于印发<企业会计准则解释第 16号>的通知》（财会〔2022〕31号）的规定和要求对公司会计政策进行变更，符 合财政部、中国证券监督管理委员会、深圳证券交易所的有关规定，能够客观、公 允地反映公司的财务状况和经营成果。相关决策程序符合法律法规和《公司章程》 等规定，不存在损害公司及全体股东特别是中小股东利益的情形。因此，我们同意 公司本次会计政策变更。 独立董事：詹 萍 胡高云 夏劲松 2023年10月28日 ...

证券代码：002412 证券简称：汉森制药 公告编号：2023-027 湖南汉森制药股份有限公司 第六届董事会第三次会议决议的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误导性陈 述或者重大遗漏。 一、董事会会议召开情况 湖南汉森制药股份有限公司（以下简称"公司"）第六届董事会第三次会议于 2023 年 10 月 26 日在公司一楼会议室以通讯方式召开，本次会议由公司董事长刘正 清先生召集主持，本次会议通知于 2023 年 10 月 17 日以专人递送、传真及电子邮件 等方式送达给全体董事、监事和高级管理人员。应参加会议董事 7 人，实际参加会议 董事 7 人，公司监事、高级管理人员列席了本次会议。本次会议的召集、召开符合《中 华人民共和国公司法》及《公司章程》的规定。 二、董事会会议审议情况 表决结果：7 票同意；0 票弃权；0 票反对。 （二）审议通过了《关于会计政策变更的议案》 公司本次会计政策变更符合《企业会计准则》等相关规定，也符合公司的实际情 况，是按照财政部相关规定要求进行的合理变更，本次会计政策变更能更加客观公正 地反映公司财务状况和经营成果，为投资者提供更加可靠、准确 ...

证券代码：002412 证券简称：汉森制药 公告编号：2023-026 湖南汉森制药股份有限公司 关于参加 2023 年湖南辖区上市公司投资者 网上集体接待日活动的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 为进一步加强与广大投资者的互动交流，湖南汉森制药股份有限公司（以下 简称“公司”）将参加由中国证券监督管理委员会湖南监管局、湖南省上市公司 协会与深圳市全景网络有限公司联合举办的“推动上市公司规范运作，保护中小 投资者——2023 年湖南辖区上市公司投资者网上集体接待日”活动，现将有关 事项公告如下： 本次活动将采取网络远程的方式举行，投资者可以登录“全景路演”网站 （http://rs.p5w.net），或关注“全景财经”微信公众号，或下载“全景路演” APP，参与本次互动交流，活动时间为2023 年 11 月 2 日（星期四）14：00 至 17：00。届时公司董事会秘书、证券事务代表将通过网络在线问答互动的形式， 就投资者关心的问题进行沟通与交流，欢迎广大投资者积极参与。 ...

股票代码：002412 股票简称：汉森制药 湖南汉森制药股份有限公司投资者关系活动记录表 编号：2023-004  特定对象调研 分析师会议 □媒体采访 业绩说明会 投资者关系 □新闻发布会 □路演活动 活动类别  现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 红思客资产：杨岌先生 东方财富：王依依女士 及人员姓名 宁波知远：李梁先生 个人投资者：陆金明先生 时间 2023 年10 月7 日（星期六）15:00-17:00 地点 湖南汉森制药股份有限公司一楼会议室 形式 现场参观 董事、副总裁：敖凌松先生 上市公司接待 副总裁、董事会秘书兼财务总监：戴江洪先生 人员姓名 总裁助理兼物料部部长：翟志强先生 证券事务代表：张希雯女士 一、参观文化展厅及车间厂区 由公司副总裁、董事会秘书兼财务总监戴江洪先生、总裁助 理兼物料部部长翟志强先生为大家讲解了公司的发展历程、 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥471,672,377.47, representing a 1.94% increase compared to ¥462,679,892.19 in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached ¥90,667,175.74, a 14.94% increase from ¥78,881,640.51 year-on-year[20]. - The net cash flow from operating activities was ¥74,689,978.03, showing a significant increase of 36.42% compared to ¥54,750,153.07 in the previous year[20]. - Basic earnings per share rose to ¥0.1802, up 14.92% from ¥0.1568 in the same period last year[20]. - The total profit for the first half of 2023 reached 100.15 million yuan, reflecting a growth of 12.30% year-on-year[35]. - The net profit after deducting non-recurring gains and losses was ¥86,178,392.83, reflecting a 15.08% increase from ¥74,886,339.66 in the same period last year[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,278,678,252.41, a decrease of 0.54% from ¥2,290,944,050.05 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company decreased by 2.58% to ¥1,845,307,130.40 from ¥1,894,131,702.92 at the end of the previous year[20]. - Cash and cash equivalents decreased by 1.56% to CNY 109,095,075.24, accounting for 4.79% of total assets[47]. - Accounts receivable increased by 0.64% to CNY 245,348,899.32, representing 10.77% of total assets[47]. - Inventory decreased by 0.34% to CNY 237,447,264.62, making up 10.42% of total assets[47]. - Long-term equity investments rose by 2.37% to CNY 831,263,844.38, which is 36.48% of total assets[47]. Cash Flow - The net cash flow from investment activities surged by 1,179.06% to ¥39,884,706.42, compared to ¥3,118,286.37 in the previous year, mainly due to increased cash received from bank wealth management and structured deposits[39]. - The net cash flow from financing activities decreased by 341.62% to -¥140,885,223.13, down from -¥31,901,607.93, primarily due to cash dividends paid amounting to ¥150,960,000.00[39]. - The cash inflow from investment activities for the first half of 2023 was ¥557,593,083.92, a substantial increase from ¥58,124,901.60 in the same period of 2022[140]. - The total cash inflow from investment activities was CNY 451,770,631.74, significantly higher than CNY 10,178,994.00 in the first half of 2022, indicating a substantial increase in investment recovery[143]. Research and Development - The company's R&D investment decreased by 8.18% to ¥21,158,772.35 from ¥23,042,775.48 in the previous year[39]. - Research and development expenses accounted for 4.2% of total revenue, highlighting the company's commitment to innovation[146]. - The company has invested in R&D for new products and generic drug consistency evaluation, which involves high costs and long cycles, posing risks to future profitability[67]. Market Position and Strategy - The company is engaged in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations[29]. - The main product, Si Mo Tang oral solution, is a unique product approved for protection and is included in the national medical insurance catalog[36]. - The company is expanding into the health industry and medical care sectors, diversifying its business operations[29]. - The marketing strategy has been enhanced with a digital approach, improving decision-making and execution efficiency[34]. - The company aims to reduce dependence on single products by diversifying its product portfolio and exploring acquisition opportunities[68]. Corporate Governance and Compliance - The company has established a comprehensive internal control system to protect the rights of shareholders and creditors[78]. - The company has a robust employee rights protection framework, ensuring compliance with labor laws and providing a safe working environment[79]. - The company actively engages in social responsibility initiatives, contributing to local economic development and community welfare[82]. - The company has not implemented any stock incentive plans or employee stock ownership plans during the reporting period[73]. - There were no major litigation or arbitration matters during the reporting period[90]. Future Outlook - The company plans to expand its market presence through new product launches and technological advancements in the upcoming quarters[146]. - Future guidance indicates a projected revenue growth of 20% for the next half of the year, driven by increased demand for its products[146]. - The management provided guidance for the next quarter, expecting a revenue growth of 10% based on current market trends and product pipeline[150]. Environmental and Social Responsibility - The company was recognized as a national-level green factory in March 2023, emphasizing its commitment to environmental protection and sustainable practices[76]. - The company has implemented measures to reduce carbon emissions and promote green office practices[77]. - There were no significant environmental penalties or issues reported during the reporting period[76].

证券代码：002412 证券简称：汉森制药 公告编号：2023-023 湖南汉森制药股份有限公司 第六届董事会第二次会议决议的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误导性陈 述或者重大遗漏。 一、董事会会议召开情况 《2023 年半年度报告》全文详见 2023 年 8 月 29 日公司指定信息披露网站巨潮 资讯网（www.cninfo.com.cn）；《2023 年半年度报告摘要》（公告编号：2023-025） 同日刊载于《证券时报》《中国证券报》《上海证券报》《证券日报》和巨潮资讯网 （www.cninfo.com.cn）。 表决结果：7 票同意；0 票弃权；0 票反对。 （二）审议通过了《2023 年半年度募集资金存放与使用情况的专项报告》 公司独立董事对本议案发表了独立意见，《2023 年半年度募集资金存放与使用 情况的专项报告》《独立董事关于公司第六届董事会第二次会议相关事项的独立意见》 详见 2023 年 8 月 29 日巨潮资讯网（www.cninfo.com.cn）。 表决结果：7 票同意；0 票弃权；0 票反对。 - 1 - 三、备查文件 湖南汉森制药股份有限公司 ...

湖南汉森制药股份有限公司 独立董事关于公司第六届董事会第二次会议 相关事项的独立意见 根据《上市公司独立董事规则》《深圳证券交易所股票上市规则》《公司章程》 等有关规定，我们作为湖南汉森制药股份有限公司（以下简称"公司"）独立董事， 现就公司第六届董事会第二次会议审议的议案，发表独立意见如下： 一、关于公司2023年半年度募集资金存放与使用情况的独立意见 经核查，公司2023年半年度募集资金的存放和使用符合中国证监会、深圳证券 交易所关于上市公司募集资金存放和使用的相关规定，符合公司《募集资金使用管 理办法》的有关规定，不存在违规存放和使用募集资金的情形。公司编制的《2023 年半年度募集资金存放与使用情况的专项报告》真实、准确、完整，客观地反映了 公司募集资金存放和使用的实际情况，不存在虚假记录、误导性陈述和重大遗漏。 我们一致同意该议案。 经审阅公司提供的相关资料，基于独立判断的立场，现就截至2023年6月30日， 公司对外担保及关联方资金占用情况，发表以下独立意见： （一）报告期内，公司未发生对外担保事项。 （二）报告期内，公司不存在为控股股东及其关联方提供担保的情况。公司与 其他关联方之间的资金往来均 ...